Phase I Clinical Trial of Substance Balance of [14C]SHR2554 in Healthy Chinese Subjects
Latest Information Update: 08 Feb 2024
At a glance
- Drugs SHR-2554 (Primary)
- Indications Lymphoma
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 30 Jan 2024 Status changed from recruiting to completed.
- 12 Oct 2023 Planned End Date changed from 3 Oct 2023 to 3 Dec 2023.
- 12 Oct 2023 Planned primary completion date changed from 26 Sep 2023 to 26 Oct 2023.